These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 7508726)

  • 21. A retrospective study of patients' out-of-pocket costs for granulocyte colony-stimulating factors.
    Tomic K; Long S; Li X; Fu AC; Yu TC; Barron R
    J Oncol Pharm Pract; 2013 Dec; 19(4):328-37. PubMed ID: 23353712
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Granulocyte colony-stimulating factor (G-CSF, filgrastim) after or during an intensive remission induction therapy for adult acute lymphoblastic leukaemia: effects, role of patient pretreatment characteristics, and costs.
    Bassan R; Lerede T; Di Bona E; Rossi G; Pogliani E; Rambaldi A; Buelli M; Viero P; Rodeghiero F; Izzi T; Corneo G; Barbui T
    Leuk Lymphoma; 1997 Jun; 26(1-2):153-61. PubMed ID: 9250800
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treatment of breast cancer with chemotherapy in combination with filgrastim: approaches to improving therapeutic outcome.
    Frasci G
    Drugs; 2002; 62 Suppl 1():17-31. PubMed ID: 12479592
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Economic analysis of filgrastim use for patients with acute myeloid leukaemia in the UK: a comparison of collection methods of resource use data.
    Standaert B; Goldstone J; Lu ZJ; Erder MH; Yin JL
    Pharmacoeconomics; 2002; 20(10):665-74. PubMed ID: 12162755
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cost-effectiveness of prophylaxis treatment strategies for febrile neutropenia in patients with recurrent ovarian cancer.
    Fust K; Li X; Maschio M; Barron R; Weinstein MC; Parthan A; Walli-Attaei M; Chandler DB; Lyman GH
    Gynecol Oncol; 2014 Jun; 133(3):446-53. PubMed ID: 24657302
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cancer treatment in Sweden--costs of drugs, inpatient and outpatient care from 1985 to 1996 and cost effectiveness of new drugs.
    Ragnarson Tennvall G; Karlsson G
    Acta Oncol; 1998; 37(5):447-53. PubMed ID: 9831373
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Economic analysis of a randomized clinical trial to compare filgrastim-mobilized peripheral-blood progenitor-cell transplantation and autologous bone marrow transplantation in patients with Hodgkin's and non-Hodgkin's lymphoma.
    Smith TJ; Hillner BE; Schmitz N; Linch DC; Dreger P; Goldstone AH; Boogaerts MA; Ferrant A; Link H; Zander A; Yanovich S; Kitchin R; Erder MH
    J Clin Oncol; 1997 Jan; 15(1):5-10. PubMed ID: 8996118
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Biosimilars of filgrastim in autologous stem cell transplant: reduction in granulocyte-colony stimulating factor costs, but similar effects on bone marrow recovery.
    Ianotto JC; Ngo Sack F; Couturier MA; Tempescul A; Mugnier N; Delepine P; Guillerm G; Berthou C
    Leuk Lymphoma; 2014 Jan; 55(1):74-7. PubMed ID: 23566160
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cost-effectiveness of autologous bone marrow transplantation.
    Lawless GD
    Am J Health Syst Pharm; 1995 Oct; 52(19 Suppl 4):S11-4. PubMed ID: 8846240
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Economic analysis of prophylactic pegfilgrastim in adult cancer patients receiving chemotherapy.
    Eldar-Lissai A; Cosler LE; Culakova E; Lyman GH
    Value Health; 2008; 11(2):172-9. PubMed ID: 18380630
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Economic implications of using pegfilgrastim rather than conventional G-CSF to prevent neutropenia during small-cell lung cancer chemotherapy.
    Tan Sean P; Chouaid C; Hettler D; Baud M; Hejblum G; Tilleul P
    Curr Med Res Opin; 2009 Jun; 25(6):1455-60. PubMed ID: 19419340
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A randomised phase II study of the efficacy, safety and cost-effectiveness of pegfilgrastim and filgrastim after autologous stem cell transplant for lymphoma and myeloma (PALM study).
    Sebban C; Lefranc A; Perrier L; Moreau P; Espinouse D; Schmidt A; Kammoun L; Ghesquieres H; Ferlay C; Bay JO; Lissandre S; Pérol D; Michallet M; Quittet P
    Eur J Cancer; 2012 Mar; 48(5):713-20. PubMed ID: 22248711
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Peripheral blood progenitor cell transplantation mobilised by r-metHuG-CSF (filgrastim); a less costly alternative to autologous bone marrow transplantation.
    Uyl-de Groot CA; Richel DJ; Rutten FF
    Eur J Cancer; 1994; 30A(11):1631-5. PubMed ID: 7530471
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Drug formulary review process for sargramostim and filgrastim: focus on analysis of adverse drug reactions.
    Kellihan MJ
    Clin Ther; 1993; 15(5):927-37. PubMed ID: 7505717
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Economic evaluations of granulocyte colony-stimulating factor: in the prevention and treatment of chemotherapy-induced neutropenia.
    Esser M; Brunner H
    Pharmacoeconomics; 2003; 21(18):1295-313. PubMed ID: 14750898
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacoeconomic evaluation of lenograstim. Conclusions and future directions.
    Menzin J; Oster G; Cour-Chabernaud V; Richard D
    Pharmacoeconomics; 1994; 6 Suppl 2():53-60. PubMed ID: 10155595
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Potential cost savings from chemotherapy-induced febrile neutropenia with biosimilar filgrastim and expanded access to targeted antineoplastic treatment across the European Union G5 countries: a simulation study.
    Sun D; Andayani TM; Altyar A; MacDonald K; Abraham I
    Clin Ther; 2015 Apr; 37(4):842-57. PubMed ID: 25704107
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Economic evaluation of prophylaxis with recombinant granulopoiesis stimulating factor].
    Antoñanzas F; Rovira J; Garuz R; Antón F
    Med Clin (Barc); 1992 Nov; 99(18):685-9. PubMed ID: 1282638
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Granulocyte colony--stimulating factor for chemotherapy-induced neutropenia in patients with small cell lung cancer : the 40% rule revisited.
    Calhoun EA; Schumock GT; McKoy JM; Pickard S; Fitzner KA; Heckinger EA; Powell EF; McCaffrey KR; Bennett CL
    Pharmacoeconomics; 2005; 23(8):767-75. PubMed ID: 16097839
    [TBL] [Abstract][Full Text] [Related]  

  • 40. White blood cell growth factor use in an outpatient oncology clinic: Lessons and opportunities learned.
    Le AT; Trovato JA
    J Oncol Pharm Pract; 2015 Jun; 21(3):213-9. PubMed ID: 24710955
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.